替代丹氨酸衍生物的C19位置抗癌作用 向NRF2-NQO1激活的食道状细胞癌
Hiroyuki Oshikiri1,2, Keiko Taguchi1, Wataru Hirose1,2
1Department of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Molecular and cellular biology
|December 24, 2024
概括
新的HSP90抑制剂,C19替代的17DMAG,在NRF2激活的癌症中显示合成致死性. 这些化合物为食道癌症治疗提供了提高疗效和降低肝毒性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 在食道状细胞癌中NRF2的遗传激活赋予了对化疗和放射治疗的耐药性,导致患者的预后不佳.
- 激活NRF2的癌症呈现出对新型治疗策略的关键需求.
- 之前对凝胺氨酸 (HSP90抑制剂) 和其衍生品17DMAG的鉴定显示了NRF2活性的合成致死性.
研究的目的:
- 设计和评估具有C19替代结构的第二代HSP90抑制剂,以克服与第一代化合物相关的肝毒性.
- 在临床前癌症模型中评估这些新型化合物的疗效和安全性,特别是那些具有NRF2-NQO1激活的癌症模型.
主要方法:
- 利用各种体外和体内癌症模型来测试C19替代的17DMAG化合物.
- 评估了与NRF2-NQO1-激活癌细胞的合成致命相互作用.
- 在异种移植小鼠瘤模型中评估了抗癌疗效和肝毒性.
主要成果:
- 用C19替代的17DMAG化合物对NRF2-NQO1激活的癌细胞表现出持续增强的毒性.
- 这些新型化合物在异种移植小鼠模型中表现出显著的抗癌疗效.
- 重要的是,在异种移植模型中没有观察到肝毒性.
结论:
- 第二代C19替代的17DMAG化合物代表了一个有前途的新类HSP90抑制剂,具有更好的临床潜力.
- 这些新型药物对NRF2-NQO1-激活癌症,包括食道癌,具有有效性,而没有早期药物的剂量限制性肝毒性.
- 患有NRF2-NQO1-激活食道癌的患者可能从这种新的治疗方法中受益.
更多相关视频
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
336
10:42Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion
Published on: July 6, 2022
3.7K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K